Skip to main content

FLU

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

EMS
EMSBrazil - Hortolândia
1 program
1
naphazoline hydrocloridePhase 31 trial
Active Trials
NCT01533220Completed132Est. Apr 2014
Sandoz
SandozAustria - Kundl
1 program
1
Influenza Trivalent Inactivated VaccinesPhase 21 trial
Active Trials
NCT00644540Completed89Est. Jun 2008
FluGen
FluGenWI - Madison
1 program
1
the H3N2 M2SR monovalent influenza vaccinePhase 1Vaccine1 trial
Active Trials
NCT02822105Completed96Est. Nov 2017
Novartis
NovartisBASEL, Switzerland
1 program
Influenza Trivalent Inactivated VaccinesPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EMSnaphazoline hydrocloride
SandozInfluenza Trivalent Inactivated Vaccines
FluGenthe H3N2 M2SR monovalent influenza vaccine

Clinical Trials (3)

Total enrollment: 317 patients across 3 trials

NCT01533220EMSnaphazoline hydrocloride

Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal

Start: Jan 2013Est. completion: Apr 2014132 patients
Phase 3Completed
NCT00644540SandozInfluenza Trivalent Inactivated Vaccines

Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

Start: Nov 2007Est. completion: Jun 200889 patients
Phase 2Completed
NCT02822105FluGenthe H3N2 M2SR monovalent influenza vaccine

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Start: Jun 2016Est. completion: Nov 201796 patients
Phase 1Completed

Related Jobs

Scientist 1

CSL BehringCSL Behring
Seqirus USA - NC - Holly Springs
1w ago
$77K - $138K/yr

Scientist 1

CSL SeqirusCSL Seqirus
Seqirus USA - NC - Holly Springs
1w ago
$74K - $132K/yr

Legal Counsel, Americas

CSL BehringCSL Behring
Seqirus USA - NJ - Summit
1mo ago
$104K - $239K/yr

Legal Counsel, Americas

CSL SeqirusCSL Seqirus
Seqirus USA - NJ - Summit
1mo ago
$100K - $229K/yr

Associate Director, US Brand Marketing

CSL BehringCSL Behring
Seqirus USA - NJ - Summit
1mo ago
$180K - $205K/yr

Associate Director, US Brand Marketing

CSL SeqirusCSL Seqirus
Seqirus USA - NJ - Summit
1mo ago
$180K - $205K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.